JP5047299B2 - ボンベシン受容体サブタイプ−３モジュレータとしての置換イミダゾール - Google Patents

ボンベシン受容体サブタイプ−３モジュレータとしての置換イミダゾール Download PDF

Info

Publication number
JP5047299B2
JP5047299B2 JP2009533350A JP2009533350A JP5047299B2 JP 5047299 B2 JP5047299 B2 JP 5047299B2 JP 2009533350 A JP2009533350 A JP 2009533350A JP 2009533350 A JP2009533350 A JP 2009533350A JP 5047299 B2 JP5047299 B2 JP 5047299B2
Authority
JP
Japan
Prior art keywords
alkyl
substituted
group
unsubstituted
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009533350A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010506919A (ja
JP2010506919A5 (enExample
Inventor
チェン，デイビッド
フランクリン，クリストファー，エル
グッゾ，ピーター，アール
リン，ライナス，エス
ロー，マイケル，エム−シー
ナーガンド，ラヴィ，ピー
セバッド，イヤースー，ケイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2010506919A publication Critical patent/JP2010506919A/ja
Publication of JP2010506919A5 publication Critical patent/JP2010506919A5/ja
Application granted granted Critical
Publication of JP5047299B2 publication Critical patent/JP5047299B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2009533350A 2006-10-20 2007-10-16 ボンベシン受容体サブタイプ−３モジュレータとしての置換イミダゾール Expired - Fee Related JP5047299B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85319306P 2006-10-20 2006-10-20
US60/853,193 2006-10-20
PCT/US2007/022087 WO2008051406A2 (en) 2006-10-20 2007-10-16 Substituted imidazoles as bombesin receptor subtype-3 modulators

Publications (3)

Publication Number Publication Date
JP2010506919A JP2010506919A (ja) 2010-03-04
JP2010506919A5 JP2010506919A5 (enExample) 2012-07-12
JP5047299B2 true JP5047299B2 (ja) 2012-10-10

Family

ID=39325111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533350A Expired - Fee Related JP5047299B2 (ja) 2006-10-20 2007-10-16 ボンベシン受容体サブタイプ−３モジュレータとしての置換イミダゾール

Country Status (13)

Country Link
US (1) US8193228B2 (enExample)
EP (1) EP2091937A2 (enExample)
JP (1) JP5047299B2 (enExample)
KR (1) KR20090064458A (enExample)
CN (1) CN101528730A (enExample)
AU (1) AU2007309570B2 (enExample)
BR (1) BRPI0717976A2 (enExample)
CA (1) CA2666310C (enExample)
IL (1) IL198004A0 (enExample)
MX (1) MX2009004112A (enExample)
NO (1) NO20091957L (enExample)
RU (1) RU2009118935A (enExample)
WO (1) WO2008051406A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083822A2 (en) 2006-10-20 2009-08-05 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
CA2667003A1 (en) 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
WO2009123164A1 (ja) * 2008-04-02 2009-10-08 塩野義製薬株式会社 血管内皮リパーゼ阻害活性を有するヘテロ環誘導体
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013135674A1 (en) * 2012-03-12 2013-09-19 Syngenta Participations Ag Insecticidal 2-aryl-acetamide compounds
CN103497159B (zh) * 2013-09-18 2015-08-12 苏州岚云医药科技有限公司 1,2-二取代-5-磺酰基咪唑类化合物的制备方法
LT3364958T (lt) 2015-10-23 2023-06-12 Navitor Pharmaceuticals, Inc. Sestrin-gator2 sąveikos moduliatoriai ir jų panaudojimas
CN116370448B (zh) 2017-04-26 2026-01-13 纳维托制药有限公司 Sestrin-gator2相互作用的调节剂及其用途
CN113164414A (zh) 2018-10-24 2021-07-23 纳维托制药有限公司 多晶型化合物和其用途
TWI870497B (zh) 2019-11-01 2025-01-21 美商奈維特製藥公司 使用mtorc1調節劑的治療方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962117A (en) 1987-11-25 1990-10-09 Merck Frosst Canada, Inc. Heterazole dialkanoic acids
WO1993017681A1 (en) 1992-03-02 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
JPH07243068A (ja) 1994-03-08 1995-09-19 Murata:Kk 金属表面の電解処理方法
WO1997040017A2 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
EA003056B1 (ru) 1996-12-23 2002-12-26 Дюпон Фармасьютикалз Компани АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ
JPH11217348A (ja) 1997-10-15 1999-08-10 Otsuka Pharmaceut Co Ltd フルオレノン誘導体の製造法
IL136637A0 (en) 1997-12-22 2001-06-14 Du Pont Pharm Co Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors
AR024077A1 (es) 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
JP3842976B2 (ja) 2000-03-17 2006-11-08 富士通株式会社 分布帰還型半導体レーザとその製造方法
ATE542805T1 (de) 2000-08-11 2012-02-15 Nippon Chemiphar Co Ppar-delta aktivatoren
US7687664B2 (en) 2001-06-04 2010-03-30 Eisai R&D Management Co., Ltd. Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it
KR100901683B1 (ko) 2001-08-10 2009-06-08 닛뽕 케미파 가부시키가이샤 퍼옥시좀 증식제 응답성 수용체 δ의 활성화제
AU2003209388A1 (en) 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
JP2003321455A (ja) 2002-02-28 2003-11-11 Nissan Chem Ind Ltd ｏ−置換ベンゾイル化合物及びこれを有効成分とする除草剤
DE10224844A1 (de) 2002-06-05 2004-01-08 Solvay Pharmaceuticals Gmbh Nicht-peptidische BRS-3-Agonisten
WO2004007464A1 (ja) 2002-07-10 2004-01-22 Sumitomo Pharmaceuticals Co., Ltd. イミダゾール誘導体
EP1556373A1 (en) * 2002-10-18 2005-07-27 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
BR0314898A (pt) 2002-11-19 2005-08-02 Galderma Res & Dev Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
WO2004048351A2 (en) 2002-11-25 2004-06-10 Galderma Research & Development, S.N.C. Biphenyl compounds which activate ppar-gamma type receptors and use thereof in cosmetic or pharmaceutical compositions
CN1747949A (zh) 2002-12-20 2006-03-15 法马西亚公司 无环吡唑化合物
WO2004071509A1 (ja) 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. オリゴデンドロサイト分化促進剤
AU2004210711B2 (en) 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
JP2007525406A (ja) 2003-12-04 2007-09-06 ワイス ビアリールスルホンアミドおよびその使用方法
GB0328796D0 (en) 2003-12-12 2004-01-14 Biofocus Plc Compounds which interact with the G-protein coupled receptor family
EP1697333A4 (en) 2003-12-17 2009-07-08 Merck & Co Inc (3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR
EP1730118A1 (en) * 2004-02-12 2006-12-13 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
GB0403578D0 (en) 2004-02-18 2004-03-24 Biofocus Discovery Ltd Compounds which interact with the G-protein coupled receptor family
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
EP2083822A2 (en) * 2006-10-20 2009-08-05 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
CA2667003A1 (en) 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators

Also Published As

Publication number Publication date
NO20091957L (no) 2009-07-17
US20100022598A1 (en) 2010-01-28
RU2009118935A (ru) 2010-11-27
CN101528730A (zh) 2009-09-09
MX2009004112A (es) 2009-05-11
IL198004A0 (en) 2009-12-24
US8193228B2 (en) 2012-06-05
CA2666310C (en) 2012-07-31
CA2666310A1 (en) 2008-05-02
JP2010506919A (ja) 2010-03-04
WO2008051406A3 (en) 2008-07-24
AU2007309570B2 (en) 2012-07-12
BRPI0717976A2 (pt) 2013-11-12
EP2091937A2 (en) 2009-08-26
KR20090064458A (ko) 2009-06-18
WO2008051406A2 (en) 2008-05-02
AU2007309570A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
JP5047299B2 (ja) ボンベシン受容体サブタイプ−３モジュレータとしての置換イミダゾール
JP5313161B2 (ja) ボンベシンレセプターサブタイプ−３調節因子としての置換ジアゼピンスルホンアミド
US8183275B2 (en) Substituted imidazoles as bombesin receptor subtype-3 modulators
JP2009537523A (ja) 三級アルコールのプロドラッグ
EP2146997B1 (en) Substituted furo[2,3-b]pyridine derivatives as cannabinoid-1 receptor modulators
US8318767B2 (en) Substituted imidazoles as bombesin receptor subtype-3 modulators
AU2006320797A1 (en) Heterocycle-substituted 3-alkyl azetidine derivatives

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120131

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120221

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120221

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120228

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120308

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120528

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120619

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120717

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150727

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150727

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees